The FDA approved a second (donanemab) that likewise removes amyloid plaques and lowers tau tangles. These agents slow the decline of cognition and daily function by 25% to 40% on average.

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla ... amyloid and tau. At some point, researchers believe, those protein clumps start ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

5 – Role of tau protein Lilly has received praise ... attention will undoubtedly shift to ongoing studies of donanemab and other amyloid therapies in patients with earlier-stage disease and ...

Not the Same. In amyloid-negative people (left) few tangles accumulate over a decade. In amyloid-positives (right), tangles grow faster in women (red) than men (blue). [Courtesy of Gillian Coughlan, ...

An oral small molecule from New York-based biotech Oligomerix curbed the tangling of tau protein in the brains of mice that ...

Requiring testing for tau could be a major break on the drug ... In its trials, Lilly stopped dosing with donanemab after amyloid plaques were cleared from the brains of treated subjects ...

Called remternetug, the medication is derived from donanemab, but is administered ... will be a cocktail of drugs that will include amyloid and tau blockers, and support for neuron regeneration ...

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...

Both lecanemab and donanemab are costly treatments that ... also provided cerebrospinal fluid (CSF) samples for amyloid beta (Aβ) and tau protein assessment. All participants underwent clinical ...

When the authors correlated t-tau and NfL concentrations with parenchymal amyloid, they again saw that protofibrils ... But why does the Aβ42/40 ratio rise during donanemab treatment, when this ...

Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the brain before it causes significant damage.